LB PHARMACEUTICALS INC 8K

LB Pharmaceuticals reported significantly higher R&D-driven losses for Q2 2026, raised $150 million in a July private placement, and advanced its late-stage LB-102 neuropsychiatric pipeline with an accelerated Phase 3 schizophrenia data timeline and extended cash runway beyond Q2 2029.

On August 11, 2026, LB Pharmaceuticals Inc. reported its unaudited financial results for the quarter and six months ended June 30, 2026 and provided a corporate update, highlighting accelerated timing for topline data from its pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia to the first half of 2027 with a planned pre-NDA meeting in the second half of 2027, continued advancement of LB-102 in bipolar depression and planned adjunctive MDD indications, and a July 2026 $150 million private placement intended to fund pipeline expansion and general corporate purposes. The company’s R&D and G&A expenses rose sharply year-over-year due to increased clinical trial, manufacturing, and personnel costs, resulting in a quarterly net loss of $51.6 million and a six-month net loss of $70.7 million, while cash, cash equivalents, and marketable securities of $327.8 million at June 30, 2026 (excluding the private placement proceeds) are expected to fund operations beyond the second quarter of 2029. The update also noted ongoing long-term safety and additional Phase 2 studies for LB-102, publication of Phase 2 schizophrenia data in JAMA Psychiatry, and the appointment of a new Senior Vice President of Clinical Operations to support the company’s expanding late-stage clinical programs.

Filing Facts

CIK

1691082

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-343479

Alert Tier

6